Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT07934056
Overview
This study will evaluate the diagnostic performance and safety of gallium-68 (68Ga)-labeled dual-target imaging agents in patients with prostate cancer. These investigational agents are designed to target either EphA2 and prostate-specific membrane antigen (PSMA), or ACP3 and PSMA, for positron emission tomography/computed tomography (PET/CT) imaging. The main aims are to assess how well these imaging agents detect prostate cancer lesions, evaluate their safety, and estimate the radiation doses received by different organs and the body as a whole. The study will also explore their potential use in early diagnosis, determining the extent of cancer spread, and detecting cancer recurrence.
Sponsor
The First Affiliated Hospital of Soochow University
Phase
Early Phase 1
ClinicalTrials.gov
NCT07934056Eligibility
Inclusion criteria not yet provided.
Help us improve your experience